chlorpheniramine
Trade name: ChlorTrimeton
Approved
Jan 4, 1984
Chlorphenamine (CP, CPM), also known as chlorpheniramine, is an antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis (hay fever). It is taken orally (by mouth). The medication takes effect within two hours and lasts for about 4–6 hours. It is a first-generation antihistamine and works by blocking the histamine H1 receptor. — Wikipedia
Clinical trial activity
19 trials · 26 clinical orgs · 7 marketing orgs
Earliest trial started Mar 12, 1996 (NCT03879772)
Timeline
1980s
1990s
- Jan 1, 1996
Earliest Phase 3 Sponsor(trial)
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
- Jun 21, 2004
Lannett Company, Inc. — NDA Secondary Org
- Sep 24, 2007
ECR Pharmaceuticals — Marketing Organization
2010s
- Oct 1, 2010
Tris Pharma, Inc. — Marketing Organization
- Jun 29, 2012
Neos Therapeutics, Inc — Marketing Organization
- Jun 29, 2012
AYTU BioScience — Marketing Organization
- Apr 30, 2015
AYTU BioScience — NDA Secondary Org
- Apr 30, 2015
Tris Pharma, Inc. — NDA Secondary Org
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Studied for
- Blood Transfusion · Phase 2
- Cold Temperature · Phase 3
- Common Cold · Phase 3
- Coronavirus Infections · Phase 2/Phase 3
- COVID-19 · Phase 2/Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Esophageal Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Influenza A virus · Phase 3
- Influenza, Human · Phase 3
- Lymphoma, T-Cell, Peripheral · Phase 2
- Nasal Obstruction · Phase 2/Phase 3
- Rhinitis, Allergic · Phase 2/Phase 3
- Rhinitis, Allergic, Seasonal · Phase 3
- Signs and Symptoms · Phase 2/Phase 3
- Sunburn · Phase 2
- Voice · Early Phase 1
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
corsym
with phenylpropanolamine
penntuss
with codeine
Also known as codeprex, tuzistra xr
tussionex pennkinetic
with hydrocodone
Also known as hydrocodone polistirex and chlorpheniramne polistirex, tussicaps
Approval history
- approvedJan 4, 1984
Chemistry & pharmacology
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- Yes
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaChlorphenamine ↗
- ChEMBLCHEMBL1201659 ↗
Also known as
- chlorpheniramine polistirex
- chlorpheniramine polistirex
- chlorpheniramine polistirex
- chlorpheniramine polistirex
- resfenol
- resfenol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06433362 | Phase 2 | Jun 1, 2024 | Harbin Medical University, Tianjin Medical University |
| NCT05858216 | Early Phase 1 (Phase 1) | May 15, 2023 | Auburn University |
| NCT05886829 | Phase 2/Phase 3 (Phase 3) | Jul 27, 2022 | Ferrer Laboratories, Hospital CEMESA Cortés, San Pedro Sula, Honduras |
| NCT05449405 | Phase 2/Phase 3 (Phase 3) | Dec 7, 2021 | Ferrer Laboratories, Hospital CEMESA Cortés, San Pedro Sula, Honduras |
| NCT04937101 | N/A | Jan 1, 2021 | Zhejiang University |
| NCT04688736 | Phase 2 | Jan 1, 2021 | Chinese Academy of Medical Sciences |
| NCT04790487 | Phase 2/Phase 3 (Phase 3) | Jul 30, 2019 | Larkin Community Hospital, Larkin Health System |
| NCT03940391 | N/A | Apr 27, 2019 | Seoul National University |
| NCT04293081 | N/A | Jan 16, 2019 | Ain Shams University |
| NCT03301454 | Phase 2 | Sep 30, 2018 | University of Lille |
| NCT03583567 | Phase 4 | Sep 5, 2018 | Mahidol University |
| NCT03332524 | Phase 2 | Jan 15, 2018 | Sephoris Pharmaceuticals LLC |
| NCT02656914 | Phase 3 | Jul 1, 2017 | EMS S/A |
| NCT02735070 | Phase 3 | Sep 1, 2016 | Brainfarma Industria Química e Farmacêutica S/A, Clinilive, CTD Dor Clinica de Diagnostico e Terapia da Dor Ltda, Hospital Nipo-Brasileiro, Pesquisare Saude S/S Ltda, Pharmagenix, Techtrials Pesquisa e Tecnologia Ltda |
| NCT01158326 | Phase 3 | Aug 1, 2010 | Federal University of Health Science of Porto Alegre, Federal University of Rio Grande do Sul |
| NCT00940836 | Phase 3 | Jun 1, 2009 | Federal University of Rio Grande do Sul |
| NCT00853190 | Phase 1 | Sep 1, 2003 | Mallinckrodt |
| NCT00853294 | Phase 1 | Sep 1, 2003 | Mallinckrodt |
| NCT03879772 | Phase 3 | Mar 12, 1996 | Merck |
Organizations
Research & Development (26)
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AYTU BioScience | For profit | NDA2 | Apr 30, 2015 |
| AYTU BioScience | For profit | MKTG | Jun 29, 2012 |
| ECR Pharmaceuticals | For profit | MKTG | Sep 24, 2007 |
| Fisons | For profit | NDA2 | May 28, 1986 |
| Lannett Company, Inc. | For profit | NDA2 | Jun 21, 2004 |
| Neos Therapeutics, Inc | For profit | MKTG | Jun 29, 2012 |
| Neos Therapeutics, Inc | For profit | SYN | Jun 29, 2012 |
| Tris Pharma, Inc. | For profit | MKTG | Oct 1, 2010 |
| Tris Pharma, Inc. | For profit | NDA2 | Apr 30, 2015 |
| UCB | For profit | NDA | Jan 4, 1984 |